Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 4Dermatologic 3Thoracic 2Genitourinary 2CNS 2Other hematologic neoplasm 1Gynecologic 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Ovarian Neoplasms 1Melanoma 1Margins of Excision 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Carcinoma, Renal Cell 1

Interventions

Carboplatin 1152Cisplatin 876Pemetrexed 834pembrolizumab 608Paclitaxel 598Docetaxel 535Gemcitabine 424Radiotherapy 377Erlotinib Hydrochloride 367Nivolumab 322Bevacizumab 322Etoposide 295durvalumab 254Drug Therapy 233osimertinib 218atezolizumab 208Radiosurgery 190Gefitinib 177Vinorelbine 145130-nm albumin-bound paclitaxel 124Magnetic Resonance Spectroscopy 121Ipilimumab 118Cetuximab 113anlotinib 104tislelizumab 103Topotecan 101Cyclophosphamide 101Taxes 99Irinotecan 95Albumin-Bound Paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × varlilumab × Thoracic × Clear all
NCT04081688 2026-02-05

Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC

Rutgers, The State University of New Jersey

Phase 1 Terminated
16 enrolled 9 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01460134 2018-01-31

A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers

Celldex Therapeutics

Phase 1 Completed
90 enrolled
DermatologicGenitourinaryGynecologicLymphoidOther hematologic neoplasmThoracic

Margins of Excision, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Ovarian Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡